Needle-free injection technology company PharmaJet said on Thursday that it has signed a Memorandum of Understanding with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma to explore the integration of needle-free delivery for inactivated polio vaccines into Egypt's national immunisation programme.
The agreement includes provisions for product distribution, localised manufacturing, technology transfer, and pharmaceutical development aimed at expanding needle-free access in Egypt and the broader region.
The UPA intends to use new technologies to reduce total immunisation costs, enhance pandemic preparedness, and strengthen foreign exchange positions. PharmaJet's Tropis needle-free system is expected to generate immunisation cost savings of 38% or more over six years, while increasing vaccine coverage and reducing hesitancy.
This collaboration supports Egypt's Universal Health Insurance project and builds on the goals of the '1000 Golden Days' presidential initiative targeting early childhood health.
PharmaJet's Tropis device has already been used in polio campaigns and has demonstrated over 94% acceptability among healthcare providers and caregivers, along with a 50% reduction in adverse events compared to needle-based delivery.
The initiative positions Egypt to become a regional hub for needle-free immunisation manufacturing and innovation across the Middle East and Northern Africa.
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001